Breaking News

Yelp Inc YELP Stock News

Yelp Inc (NYSE: YELP) was off to a relatively normal day in the market today. There wasn’t much by way of gains or declines. However, that changed minutes ago when a rumor caused excitement among investors. The stock quickly shot upward, leading to an alert from our partners at Trade Ideas. At the moment (10:39), YELP is trading at $29.99 per share after a gain of $0.63 per share (2.15%) thus far today.





YELP Gains On Takeover Rumors

As mentioned above, Yelp was off to a relatively normal day in the market this morning until minutes ago when a rumor broke and excited investors. The rumor is that the company may soon be taken over. However, it is an overwhelmingly vague rumor. The rumor doesn’t mention who the potential buyer is, nor at what price the potential takeover would take place. The rumor is simply that the company will be taken over soon.




It’s important to remember that rumors are common in the market. In fact, in the first half of this year, we’ve already seen several takeover rumors surrounding YELP; none of which, might I add, have proven to be valid. With that said, I’d be willing to bet my bottom dollar that this is just another invalid rumor. So, if you’re going to trade on it, please do so with caution.

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on YELP. In particular, we’ll be following the rumor to see if a takeover does indeed come to fruition. While our opinion is that the rumor is invalid, anything can happen in the market. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 478
TrovaGene Inc TROV Stock News

TrovaGene Inc (NASDAQ: TROV) is off to an incredible start to the trading session this morning, and for good reason. The company issued a PR informing investors of an agreement that will drive revenue. Of course, this led to excitement among investors, prompting gains in the value of the stock. As is almost always the case, our partners at Trade Ideas were the first to alert us to the movement. At the moment (10:05), TROV is trading at $1.22 per share after a gain of $0.27 per share or 28.75% thus far today.





TROV Gains On ctDNA Agreement

As mentioned above, TrovaGene is having an incredibly strong day in the market thus far today following the issuance of a press release. In the release, investors learned that the company has entered into an agreement with a worldwide, premier biopharmaceutical company. Under the agreement, TROV will provide Trovera® urine circulating tumor DNA (ctDNA) biomarker tests and services.

As a result of this agreement, TROV will be providing urine and blood biopsy tests. These tests will be used to assess and monitor mutation status in clinical trials of potential first-in-class or best-in-class oncology therapeutics that are currently under development. In a statement, Bill Welch, CEO at TROV, had the following to offer…




We’re pleased to have our liquid biopsy tests included in the clinical trials with a leading biopharmaceutical company and to participate in their development of transformative therapies to improve the lives of cancer patients worldwide… This agreement follows a separate, recent announcement of our collaboration with AstraZeneca and demonstrates the value of our Trovera® biomarker technology.”

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on TROV. In particular, we’re interested in following the company through the ongoing work surrounding the Trovera® biomarker tests. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









DryShips Inc. DRYS Stock News

DryShips Inc. (NASDAQ: DRYS) is having an overwhelmingly rough day in the market today, and for good reason. Ultimately, the declines are a side effect of the 1 for 5 reverse stock split that took effect today. Of course, this split is leading to concerns among investors, causing the losses and prompting our partners at Trade Ideas to alert us to the movement. At the moment (9:39), DRYS is trading at $3.33 per share after a loss of $0.92 per share (21.65%) thus far today.





DRYS Moves Forward With A Reverse Stock Split

As mentioned above, DryShips has been forced to move with yet another reverse stock split. The split was a 1 for 5, which means that for every 5 shares, investors now have 1 share that, at the time of the split, was worth 5 old shares. As we know, that value didn’t stick around for long.




The truth of the matter is that when we look at why DRYS needed to move forward with the split, it’s clear as to why investors are reacting negatively to it. At the end of the day, the NASDAQ has a rule that all stocks must maintain a price of $1 per share or more. Trading below that $1 puts listed companies at risk of being delisted. With the price under $1, the management team at DRYS couldn’t come up with a way to push the value up and they surely weren’t going to invest their own money. So, once again the company did what they have been known to do, push the value up at the expense of investors.

The truth of the matter is that this isn’t the first reverse split out of DryShips recently. In fact, reverse splits seem to be a common occurrence surrounding the stock. That’s because the stock has taken a dive over the past year, in fact, it has lost a dramatic amount of money year to date. If we take away all of the reverse stock splits, it’s easy to see that DRYS has lost approximately 99.9% of its value year to date. To put that into perspective, if you had $100 invested in the company on January 1st, you now have about a dollar left!

Ditch This Warm Pile Of Manure!

The bottom line is that DRYS simply doesn’t have a leg to stand on. George Economou, the CEO of the company has poisoned the stock with toxic financing while he continues to take an exorbitant salary at the expense of investors. Through the process of loaning the company money at exorbitant rates, and laying the risk of these loans on DryShips, Economou has set a plan in place by which he is able to take the money you invest and liquidate it into cash that’s destined for his own pocket.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

The Bottom Line

I’ve been saying this for some time now. DRYS will eventually make it to zero and those holding shares of the stock will be left holding an empty bag of Economou branded manure that’s too toxic to fertilize your roses with! Don’t trust me, do your own DD. Perform a couple of searches, learn about previous stock splits, dig into the finances, and take a look at Kalani investments. When you do, make sure you’re sitting down; the surprising picture would be enough to knock even the SEC off of their feet. That is, if they took the time to investigate!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 481
DarioHealth DRIO Stock News

DarioHealth Corp (NASDAQ: DRIO) is having an incredibly strong start to the trading session this morning, and for good reason. The company announced increased coverage with regard to providers in the diabetes industry. With such positive news, investors excitedly have been pushing the stock upward throughout the morning. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. At the moment (10:19), DRIO is trading at $2.19 per share after a gain of $0.06 per share or 2.66% thus far today.





DRIO Gains On Coverage News

As mentioned above, DarioHealth is having a strong day in the market today after announcing expanded insurance coverage. The company said that it would be expanding its insurance coverage provider network across the United States with additional service providers that will be able to target up to 10 million customers with diabetes. In a statement, Erez Rphael, Chairman and CEO at DRIO, had the following to offer…




Our goal is to deliver the Dario(TM) Blood Glucose Monitoring System into as many hands of those who need it, and with the additional insurance coverage option, we expect to have the capabilities to cover up to 30% of consumers in the U.S. diabetes market.

In just a few months since launching our insurance health coverage initiative, we have received tremendous feedback and we are able to offer insurance reimbursement from companies such as Aetna, United HealthCare, and various Blue Cross Blue Shield organizations. As such, we have signed on additional partners to increase our U.S. market penetration.”

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on DRIO. In particular, we’re interested in following the ongoing work with regard to the company’s insurance initiative and excited to continue seeing positive results. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Seanergy Maritime Holdings Corp. SHIP Stock News

Seanergy Maritime Holdings Corp. (NASDAQ: SHIP) is off to an incredible start to the trading session this morning, and for good reason. The company released new slides providing corporate updates. Of course, this led to excitement among investors and gains in the value of the stock. As is almost always the case, our partners at Trade Ideas were the first to alert us to the gains. At the moment (11:06), SHIP is trading at $0.83 per share after a gain of $0.13 per share (17.89%) thus far today.




SHIP Gains Big On Updated Slides

As mentioned above, Seanergy Maritime Holdings is having an incredibly strong day in the market today after releasing new slides that provide an update with regard to the corporation. Here are the key points offered in the presentation:



  • Modern, high quality fleet concentrating on Capesize vessels
  • Experienced management team and committed company sponsor
  • Strong relationships with leading dry bulk charters
  • Low Capesize acquisition costs and competitive cost structure
  • Solid corporate governance – no related party transactions in ship management or ship operations
  • Access to public capital markets through NASDAQ listing
  • Drybulk market fundamentals favor Capesize vessels over the next 5 years.

To view the entire presentation, click here.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on SHIP. In particular, we’re interested in following the company’s ongoing work to take a large share of the Capesize vessel market. We’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 2052
Bristol-Myers Squibb Co BMY Stock News

Bristol-Myers Squibb Co (NYSE: BMY) is is experiencing a relatively strong spike in the market at the moment, and for good reason. There are rumors surfacing that the company will soon be taken over. Of course, these rumors are leading to excitement among investors, sending the stock upward. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (10:45), BMY is trading at $55.88 per share after a gain of $0.22 per share (0.40%) thus far today.





Rumors Suggest That PFE May Buy BMY

As mentioned above, the spike that BMY is seeing in the market at the moment has to do with the idea that the company will soon be taken over. Currently, rumors are breaking all over the social space that Pfizer Inc. (NYSE: PFE) is interested in taking the company over. However, there is no indication at what price, nor confirmation from either side at the moment.




It’s important to remember that rumors like this are common in the market. In fact, there was a rumor just a few months ago that PFE was interested in taking BMY over, but the rumor never came to fruition. With that said, it is unlikely that this takeover is going to happen. So, if you’re going to trade on this news, please do so with caution.

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on both BMY and PFE. In particular, we’re interested in following the story surrounding the potential takeover. While it is unlikely that the rumor is correct, if it is, the takeover would likely generate an incredible return of value for investors. We’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 1204
ACADIA Pharmaceuticals ACAD Stock News

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is having a strong start to the trading session this morning after rumors broke surrounding the company. The rumors led to excitement which sent the stock toward the sky, prompting our partners at Trade Ideas to alert us to the gains. At the moment (10:30), ACAD is trading at $29.49 per share after a gain of $1.27 per share (4.50%) thus far today.





ACAD Gains On Takeover Rumor

As mentioned above, ACADIA is having a wonderful start to the trading session this morning as rumors circle social media. The rumor is that the company will soon be taken over. This is something that we’ve seen often surrounding ACAD recently. The rumor today doesn’t suggest who the buyer might be nor at what price. In fact, it’s overwhelmingly vague.




When trading on this type of news, it’s important to keep in mind that rumors are nothing new to the market. In fact, they happen all the time, with very few of them proving to be true. In this particular case, we believe the rumor lacks validity. First and foremost, this is about as vague as vague market rumors get. On top of that, we’ve seen a few rumors surrounding ACAD recently, none of them proving to be true. So, if you’re going to try and turn a profitable trade off of this move, please make sure to move with caution.

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on ACAD. In particular, we’re interested in following the rumors surrounding the potential takeover. While we don’t believe that these rumors are true, anything could happen in the market, and a takeover would yield incredible value for shareholders. We’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Netflix, Inc. NFLX Stock News

Netflix, Inc. (NASDAQ: NFLX) is off to an incredibly strong run in the market at the moment, and for good reason. There’s a rumor that a billionaire investor has a stake in the stock. Of course, this led to excitement among investors, causing gains and prompting our partners at Trade Ideas to alert us to the movement. At the moment (10:16), NFLX is trading at $154.47 per share after a gain of $2.42 per share (1.59%) thus far today.





NFLX Gains On Buffet Stake Rumor

As mentioned above, Netflix is making a run for the top at the moment as the result of a rumor that’s surfacing on social media. The rumor is that Warren Buffet has taken a stake in the company. However, the rumor doesn’t suggest what type of stake it is (activist or passive), nor does the rumor suggest the size of the stake that Buffet supposedly has in NFLX.




It’s important to remember that rumors are abundantly common in the market. In most cases, these rumors prove to be invalid. While it’s understandable that Buffet may be interested in NFLX at the moment, there is no confirmation, no SEC filing, and nothing else that suggests that this rumor is true. So, if you’re going to trade on this one, please be sure to do so with caution.

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on NFLX. In particular, we’re interested in following the news surrounding Warren Buffet’s potential stake in the company. We’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Advanced Micro Devices, Inc. AMD Stock News

Advanced Micro Devices, Inc. (NASDAQ: AMD) is having a great morning in the market this morning, and for good reason. The company released details with regard to its newest offering, one that’s likely to cause some pain for Intel (INTC). Of course, our partners at Trade Ideas were the first to alert us to the gains. Currently (9:37), AMD is trading at $13.47 per share after a gain of $0.83 per share or 6.60% thus far today.





AMD Takes On Xeon With Epyc

As mentioned above, yesterday proved to be a great day for Advanced Micro Devices as the company launched its newest processor, known as Epyc. The company’s goal with this processor seems to be to take market share from Intel in the data center and enterprise server space, and if you look at how the stock is reacting, it’s clear that investors believe that AMD has a fighting chance in the industry, but why wouldn’t they?




The new Epyc processors are, well, epic. The processor has been built around Zen architecture. The processors will range from Epyc 7251, which is an 8 core, 16 thread chip running between 2.1 and 2.9 GHz in a 120W power invelope, to the Epyc 7601, which is a 32 core, 64 thread chip running at 2.2 to 3.2GHz with a 180W design power. For those of you who aren’t sure what all that means, it simply means that AMD has created the best processor on the market today, stepping on Intel’s toes in the data center and enterprise server space.

Intel Vows To Top Epyc

While Epyc has investors clamoring for more AMD, Intel is hoping to make this a short term trend. In fact, the company released a statement, vowing to top the Epyc processors. Here’s what they had to say…

We take all competitors seriously, and while AMD is trying to re-enter the server market segment, Intel continues to deliver 20+ years of uninterrupted data center innovations while maintaining broad ecosystem investments. Our Xeon CPU architecture is prove and battle tested, delivering outstanding performance on a wide range of workloads and specifically designed to maximize data center performance, capabilities, reliability, and manageability. With our next-generation Xeon Scalable processors, we expect to continue offering the highest core and system performance versus AMD. AMD’s approach of stitching together 4 desktop die in a processor is expected to lead to inconsistent performance and other deployment complexities in the data center.

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on AMD. In particular, we’re interested in following the Epyc processor takeoff. While Intel has pointed out what they believe to be an issue, the overall consensus is that Epyc is the best thing on the market to date. Nonetheless, it will be interesting to see what INTC comes up with to compete with Epyc. We’ll continue following the story closely and bringing the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 10833
Delcath Systems, Inc. DCTH Stock News

Delcath Systems, Inc. (NASDAQ: DCTH) is having yet another incredible day in the market today. Investors seem to be putting full faith and support in the CEO of the company and his driving effort to turn things around. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (11:09), DCTH is trading at $0.18 per share after a gain of $0.08 per share (80.71%) thus far today.





DCTH Is Having Yet Another Exceptional Day In The Market

Delcath has been running upward in the market for the past several trading sessions, and for good reason. Investors are putting their full support into Jennifer Simpson, the CEO of the company that is striving for excellence.




At the moment, the key for Simpson, and the investors that are backing her, is getting the stock to $1 per share before it is delisted from the NASDAQ. Of course, with the stock trading at $0.18 per share, that’s a tall order. In fact, a reverse split was proposed to investors to push the stock to that direction. However, the company didn’t receive the votes it needed for the split.

Nonetheless, the bulls believe that delisting isn’t going to be an issue. In fact, if you take a look at StockTwits at the moment. You’ll see several bulls saying that the stock will hit $1 by Friday.

So, What’s The Value Proposition Here?

The answer to the question above is a relatively simple one. Ultimately, the value proposition is the company’s proprietary Hepatic Delivery System. Currently, the company is working on a Phase 2 clinical trial evaluating the combination of Melphalan with the Hepatic Delivery System for the treatment of both liver cancer and bile duct cancer. There’s also a Phase 3 clinical trial in which DCTH is investigating Melphalan Hydrochloride for injection for use with the Hepatic Delivery System in patients with Hepatic Dominant Ocular Melanoma.

The True Value Is A Potential Acquisition

At the end of the day, the oncology space is an incredibly competitive one. One where acquisitions happen all the time in order to maintain or increase dominance. Well, DCTH is likely a perfect takeover target. Even after the strong run we’ve seen on the stock as of late, the market cap remains relatively low at just $64 million. That’s pennies in the oncology space, and with multiple clinical trials, there’s no reason that a larger player wouldn’t be willing to put up some change for the company. Of course, doing so quickly would allow the larger player to get a hefty discount!

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on DCTH. In particular, we’ll be following the company closely to see what CEO Jennifer Simpson pulls out of her hat to bring the stock to $1 per share. In the longer term, we’re interested in following the ongoing clinical trials and watching for a takeover offer, as with the value proposition offered here, it’s likely not a matter of if, but a matter of when. Nonetheless, we’ll continue to follow the news closely and bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Thought Leader Discussions

Gevo, Inc. GEVO Stock News

0 5500
Gevo, Inc. (NASDAQ: GEVO) Before we get into this interview, I'd like to extend a special thanks to my friend Joey who both set up the...